" class="no-js "lang="en-US"> Drug Development Archives - Medtech Alert
Sunday, March 03, 2024

Sort by:

Date

Top Post

Google Cloud Launches AI-powered Solutions to Safely Accelerate Drug Discovery and Precision Medicine

Google Cloud has announced two new AI-powered life sciences solutions to accelerate drug discovery and […]

Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 for Prader-Willi Syndrome

Acadia Pharmaceuticals today announced the addition of a new Phase 3 development candidate to its […]

Heligenics Unveils A First-Of-Its-Kind Precision Prescription Test For Breast Cancer Therapeutics

Heligenics, a cutting-edge biotech company, announces a first-of-its-kind precision genetic test to select among drugs […]

Biostar Pharma Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule (UTD2)--The World's First Oral Epothilone Anti-Cancer Drug

Biostar Pharma, the US subsidiary of Beijing Biostar Pharmaceuticals which is a synthetic biology-driven biopharma […]

Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors

Lantern Pharma, an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary […]

FDA Advisory Committee Votes Unanimously to Confirm Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Early Alzheimer's Disease

BioArctic AB‘s partner Eisai announced that the US Food and Drug Administration’s (FDA) Peripheral and […]

Gilteritinib as Maintenance Therapy Demonstrated Benefit in Subgroups of FLT3-ITD Acute Myeloid Leukemia Patients

Astellas Pharma and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) has presented […]

Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430

Astellas Pharma and Kate Therapeutics have announced an exclusive license agreement to develop and commercialize KT430. […]

FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals and CRISPR Therapeutics today announced that the United States Food and Drug Administration (FDA) […]

Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

Rocket Pharmaceuticals, a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic […]

GSK Receives US FDA File Acceptance for Jemperli (dostarlimab) plus Chemotherapy for the Treatment of dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

GSK has announced the US Food and Drug Administration (FDA) accepted the supplemental Biologics License […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more